HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Immune Checkpoint Inhibitors in Vaccines

Immune checkpoint inhibitors are increasingly being integrated with vaccine strategies to enhance immune responses against diseases like cancer. These inhibitors target immune checkpoints—regulatory pathways in immune cells that, when activated, prevent an overactive immune response. However, tumors often exploit these checkpoints to evade immune attack. By combining vaccines with checkpoint inhibitors, vaccines can stimulate a targeted immune response against tumor antigens, while inhibitors ensure the immune system maintains an aggressive stance against the tumor. This combination has shown significant promise in clinical trials, leading to prolonged responses and improved survival in cancers like melanoma. Immune checkpoint inhibitors like PD-1 and CTLA-4 inhibitors are now being studied in vaccine formulations, with the goal of transforming immune cells into potent fighters against cancer cells, leading to potentially transformative outcomes in oncology.

Tags

Submit your abstract Today

Watsapp